A lesson learned from PTK-targeted therapies in chronic myeloid leukemia (BCR-ABL)[46-48] and NSCLC (EGFR mutants, ALK and ROS1 fusions)[49-53] is that the secondary mutations in the targeted PTK can cause resistance to the TKIs. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.